Medtronic vs Sanofi

Medtronic (MDT), health care, and Sanofi (SNY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Medtronic is worth $132.1B on the stock market and Sanofi $115B: Medtronic is valued at 15% more. Medtronic trades at 25.4 times earnings and Sanofi at 23.8; operating margins in their latest fiscal years were 17.8% and 14.5%. Over the past year Medtronic's share price has moved +2.06% and Sanofi's -4.48%.

Key facts

Medtronic market value
$132.1B
Sanofi market value
$115B
Medtronic P/E
25.4
Sanofi P/E
23.8
Medtronic revenue
$36.4BFY to 2026-04-24
Sanofi revenue
$48.4BFY to 2025-12-31
Superinvestors holding both
2

Market values as of .

Medtronic vs Sanofi: every measure side by side
Measure Medtronic Sanofi
SectorHealth CareHealth Care
Country Ireland France
Fiscal year ends2026-04-242025-12-31
Size
Market cap$132.1Bhigher$115Blower
Revenue$36.4Blower$48.4Bhigher
Earnings$4.8Blower$8.7Bhigher
Employees95,000higher74,846lower
Total assets$93Blower$140.7Bhigher
Valuation
P/E25.4higher23.8lower
P/S3.6higher2.4lower
P/B——
Dividend yield——
Profitability
Operating margin17.8%higher14.5%lower
Balance sheet
Net assets$49.5Blower$79.2Bhigher
Total liabilities$43Blower$61.1Bhigher
Total debt$28Bhigher$20.8Blower
Cash on hand$1.9Blower$8.5Bhigher
Price change
Today+0.38%higher-1.05%lower
1 year+2.06%higher-4.48%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Medtronic / Sanofi). Who owns MDT · Who owns SNY

Further comparisons

Learn

Questions and answers

Which is bigger, Medtronic or Sanofi?

By market value, Medtronic is the larger: $132.1B against $115B for Sanofi. By revenue in its latest fiscal year, Sanofi is the larger: $48.4B against $36.4B for Medtronic.

Which has the higher P/E ratio?

Medtronic: 25.4, against 23.8 for Sanofi. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Medtronic: 17.8%, against 14.5% for Sanofi. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Medtronic: $28B, against $20.8B for Sanofi. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Medtronic and Sanofi?

In their latest 13F filings, Richard Pzena and Dodge & Cox team hold both.

Cite this page

Funkfolio, “Medtronic vs Sanofi”, data as of 17 November 2026. https://funkfolio.com/compare/mdt-vs-sny

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.